Dry Run of the ScreenUrSelf Trial
- Conditions
- HPV-Related Cervical CarcinomaCervical Intraepithelial NeoplasiaHuman Papilloma VirusCervical Cancer
- Interventions
- Device: Evalyn BrushDevice: Colli-Pee Small Volumes
- Registration Number
- NCT05996796
- Lead Sponsor
- Universiteit Antwerpen
- Brief Summary
The proposed study is the Dry Run preceding the ScreenUrSelf trial.
- Detailed Description
The ScreenUrSelf trial will be embedded in the Flemish organized cervical cancer screening program. The goal of ScreenUrSelf is to reach women who are eligible but do not participate in cervical cancer screening, by offering two self-sampling methods (first-void urine and vaginal) in an opt-in and -out strategy (total of four interventions) to collect samples for primary high-risk (hr) Human Papillomavirus (HPV) testing, and if positive, reflex 1) cytology on a Pap smear (standard of care) and 2) methylation marker triage (index test). The two control arms include 1) no intervention; and 2) sending (recall) invitation letters to women, inviting them to make an appointment for a Pap smear (i.e., current practice within the organized cervical cancer screening program in Flanders).
The Dry Run which is the subject of this clinical trial will test the study materials and data flows developed for the interventional study arms (C, D, E and F) of the ScreenUrSelf trial. The primary outcome of the Dry Run is to check if the flow for data- and sample collection is ready for start of the ScreenUrSelf trial, and if optimizations are deemed necessary before start of the trial.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 38
-
Eligible for cervical cancer screening within the organized Population-based Screening Program in Flanders:
- Female
- Residing in Flanders, Belgium
- No history of total hysterectomy
- No (former) diagnosis of cervical or uterine cancer
- 30 - 64 years old (birth year 1959 - 1992)
- Being pregnant or 6 weeks postpartum (self-reported after receiving the study letter/package)
- Participation during menstruation or within the 3 following days is a contraindication
- Not able to understand the study materials and participation form (informed consent form)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Opt-in vaginal self-sample Evalyn Brush Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a vaginal self-sampling study package. The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab. Opt-out first-void urine Colli-Pee Small Volumes Women will receive a first-void urine self-sampling study package at home. The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab. Opt-in first-void urine Colli-Pee Small Volumes Women will receive a letter at home with instructions how to order (via phone, e-mail, or webform) a first-void urine self-sampling study package. The study package will include an invitation letter/informed consent form, information brochure, first-void urine self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab. Opt-out vaginal self-sample Evalyn Brush Women will receive a vaginal self-sampling study package at home. The study package will include an invitation letter/informed consent form, information brochure, vaginal self-sampling device, safety bag with absorbent paper, pre-stamped return envelope, and instructions explaining how to collect the sample and send it to the lab.
- Primary Outcome Measures
Name Time Method HPV DNA using the Riatol qPCR HPV genotyping assay Through study completion, an average of 1 year HPV DNA concentration \[copies/µl DNA\] in self-samples from all study participants.
- Secondary Outcome Measures
Name Time Method Human DNA (Beta-globin) using the Riatol qPCR HPV genotyping assay Through study completion, an average of 1 year Human DNA concentration \[copies/µl DNA\] in self-samples from all study participants
Preferences Through study completion, an average of 1 year Preferences and attitudes of women regarding self-sampling (measured using a questionnaire)
Trial Locations
- Locations (1)
Universiteit Antwerpen
🇧🇪Edegem, Antwerp, Belgium